<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Hodgkin Lymphoma<BR>                     <BR>                        The efficacy of ADCETRIS in patients with HL who relapsed after autologous stem cell transplant was evaluated in one open-label, single-arm, multicenter trial. One hundred two patients were treated with 1.8 mg/kg of ADCETRIS intravenously over 30 minutes every 3Â weeks. An independent review facility performed efficacy evaluations which included overall response rate (ORR = complete remission [CR] + partial remission [PR]) and duration of response as defined by clinical and radiographic measures including computed tomography (CT) and positron-emission tomography (PET) as defined in the 2007 Revised Response Criteria for Malignant Lymphoma (modified).<BR>                        The 102 patients ranged in age from 15-77 years (median, 31 years) and most were female (53%) and white (87%). Patients had received a median of 5 prior therapies including autologous stem cell transplant.<BR>                        The efficacy results are summarized in Table 2. Duration of response is calculated from date of first response to date of progression or data cutoff date.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="SPLSERV-3F5BADEF-B17E-89BB-6585-670CBEFC1908" border="0" cellpadding="0" width="80%"><BR>                           <caption>Table 2: Efficacy Results in Patients with&#160;Hodgkin Lymphoma</caption><BR>                           <colgroup><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                           </colgroup><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Toprule">&#160;</td><BR>                                 <td align="center" colspan="3" styleCode="Botrule Lrule Rrule Toprule">N = 102</td><BR>                              </tr><BR>                              <tr><BR>                                 <td rowspan="2" styleCode="Botrule Lrule">&#160;</td><BR>                                 <td align="center" rowspan="2" styleCode="Botrule Lrule">Percent (95%CI)</td><BR>                                 <td align="center" colspan="2" styleCode="Botrule Lrule Rrule">Duration of Response, in months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">Median (95% CI)</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">Range</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;CR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">32 (23, 42)</td><BR>                                 <td align="center" styleCode="Botrule Lrule">20.5 (12.0, NE<footnote ID="SPLSERV-23CDBE20-C2BF-5514-1849-762D4D11C876">Not estimable</footnote>  )</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">1.4 to 21.9<footnote ID="SPLSERV-E3800785-7F7B-DE87-77A5-2C9553C631BA">Follow up was ongoing at the time of data submission.</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;PR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">40 (32, 49) &#160;</td><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;3.5 (2.2, 4.1)</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">&#160;1.3 to 18.7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;ORR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">73 (65, 83)</td><BR>                                 <td align="center" styleCode="Botrule Lrule">6.7 (4.0, 14.8)</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">1.3 to 21.9<footnoteRef IDREF="SPLSERV-E3800785-7F7B-DE87-77A5-2C9553C631BA"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Systemic Anaplastic Large Cell Lymphoma<BR>                     <BR>                        The efficacy of ADCETRIS in patients with relapsed sALCL was evaluated in one phase 2 open-label, single-arm, multicenter trial. This trial included patients who had sALCL that was relapsed after prior therapy. Fifty-eight patients were treated with 1.8 mg/kg of ADCETRIS administered intravenously over 30 minutes every 3 weeks. An independent review facility performed efficacy evaluations which included overall response rate (ORR = complete remission [CR] + partial remission [PR]) and duration of response as defined by clinical and radiographic measures including computed tomography (CT) and positron-emission tomography (PET) as defined in the 2007 Revised Response Criteria for Malignant Lymphoma (modified).<BR>                        The 58 patients ranged in age from 14-76 years (median, 52 years) and most were male (57%) and white (83%). Patients had received a median of 2 prior therapies; 26% of patients had received prior autologous stem cell transplant. Fifty percent (50%) of patients were relapsed and 50% of patients were refractory to their most recent prior therapy. Seventy-two percent (72%) were anaplastic lymphoma kinase (ALK)-negative.<BR>                        The efficacy results are summarized in Table 3. Duration of response is calculated from date of first response to date of progression or data cutoff date.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="SPLSERV-190065A4-DB0C-4916-8396-008E4CD8BAA9" border="0" cellpadding="4" width="80%"><BR>                           <caption>Table 3: Efficacy Results in Patients with Systemic Anaplastic Large Cell Lymphoma</caption><BR>                           <colgroup><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                              <col width="25%"/><BR>                           </colgroup><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule Toprule">&#160;</td><BR>                                 <td align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule">N = 58</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" rowspan="2" styleCode="Botrule Lrule">&#160;</td><BR>                                 <td align="center" rowspan="2" styleCode="Botrule Lrule">Percent (95%CI)</td><BR>                                 <td align="center" colspan="2" styleCode="Botrule Lrule Rrule">Duration of Response, in months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">Median (95% CI)</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">Range</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">CR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">57 (44, 70)</td><BR>                                 <td align="center" styleCode="Botrule Lrule">13.2 (10.8, NE<footnote ID="SPLSERV-A266CE32-52CF-22FB-79FA-BE31E58BBECE">Not estimable</footnote>  )</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">0.7 to 15.9<footnote ID="SPLSERV-812A64FF-8D90-AE00-46B8-6F2F7517E378">Follow up was ongoing at the time of data submission.</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">PR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;29 (18, 41)</td><BR>                                 <td align="center" styleCode="Botrule Lrule">&#160;2.1 (1.3, 5.7)</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">0.1 to 15.8<footnoteRef IDREF="SPLSERV-812A64FF-8D90-AE00-46B8-6F2F7517E378"/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Botrule Lrule">ORR</td><BR>                                 <td align="center" styleCode="Botrule Lrule">86 (77, 95)</td><BR>                                 <td align="center" styleCode="Botrule Lrule">12.6 (5.7, NE<footnoteRef IDREF="SPLSERV-A266CE32-52CF-22FB-79FA-BE31E58BBECE"/>  )</td><BR>                                 <td align="center" styleCode="Botrule Lrule Rrule">0.1 to 15.9<footnoteRef IDREF="SPLSERV-812A64FF-8D90-AE00-46B8-6F2F7517E378"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>